KPV 5 mg

Dragon Pharma KPV

KPV 5 mg represents a sophisticated approach to inflammation modulation through targeted peptide signaling. This synthetic tripeptide, comprising the amino acid sequence Lysine-Proline-Valine (KPV), is derived from the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH) and offers researchers a potent tool for investigating anti-inflammatory pathways, gut barrier integrity, and immune system regulation. Each vial contains 5 mg of pharmaceutical-grade KPV, manufactured in Dragon Pharma's EU-certified facilities using solid-phase peptide synthesis with HPLC purification to ensure molecular precision and reproducible biological activity.

KPV operates through a dual mechanism of action that distinguishes it from conventional anti-inflammatory agents. Primarily, it activates melanocortin receptors (particularly MC1R and MC3R), initiating intracellular signaling cascades that suppress nuclear factor kappa B (NF-κB) translocation—the master regulator of pro-inflammatory gene expression. Simultaneously, KPV modulates cytokine production, reducing interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) while promoting anti-inflammatory interleukin-10 (IL-10) secretion. This balanced approach allows for targeted inflammation reduction without the systemic immunosuppression associated with corticosteroids or NSAIDs. For researchers examining inflammatory responses to intense training or performance compounds like Trenbolone 100 or Anadrol Inj 50, KPV offers insights into peptide-mediated inflammation control.

The unique properties of KPV stem from its minimalistic tripeptide structure, which provides exceptional bioavailability, rapid systemic distribution, and resistance to enzymatic degradation compared to larger peptide fragments. Research indicates KPV effectively crosses mucosal barriers, making it particularly valuable for investigating gut inflammation and intestinal permeability—common concerns for athletes using oral compounds or experiencing exercise-induced gastrointestinal stress. Its small size allows for both systemic effects when administered subcutaneously and localized action when used orally or topically, offering researchers versatile administration routes for different experimental designs. When compared to other anti-inflammatory peptides like BPC-157, KPV provides complementary mechanisms focused specifically on inflammation resolution rather than tissue repair.

Dragon Pharma's KPV formulation maintains the native L-configuration of amino acids essential for receptor recognition and biological activity. The lyophilized powder ensures maximum stability for research applications, easily reconstituted with sterile water or saline for precise dosing in experimental models. For investigators studying the intersection of inflammation, recovery, and performance, KPV provides a unique window into how peptide signaling might modulate exercise-induced inflammation, accelerate recovery between training sessions, and potentially mitigate inflammatory responses to intense physical stress. Its research applications extend to potential synergistic effects with recovery peptides like TB-500, where inflammation control complements cellular migration and tissue repair processes.

Key Research Applications:

• Gut Barrier Integrity Investigation: Models protection against intestinal permeability, reduction of gut inflammation, and restoration of mucosal homeostasis—particularly relevant for oral compound research and exercise-induced gastrointestinal stress studies.
• Systemic Inflammation Modulation: Examines reduction of circulating inflammatory cytokines (IL-1β, IL-6, TNF-α) and CRP levels without immunosuppressive effects, offering insights into balanced immune regulation.
• NF-κB Pathway Analysis: Studies inhibition of nuclear factor kappa B translocation and subsequent pro-inflammatory gene expression, providing mechanistic understanding of inflammation control at transcriptional level.
• Exercise-Induced Inflammation Research: Investigates modulation of post-exercise inflammatory responses, potentially accelerating recovery and reducing muscle soreness through cytokine regulation.
• Immune System Balancing Studies: Explores melanocortin receptor-mediated immune modulation that reduces excessive inflammation while maintaining protective immune responses against pathogens.

Each 2 mL vial contains 5 mg of research-grade KPV tripeptide, synthesized and purified under strict quality control standards in Dragon Pharma's certified European facilities for investigative use in approved research protocols.

Product Specifications

Research Guidelines

KPV can be administered via multiple routes in preclinical research: subcutaneous injection for systemic effects, oral administration for gut-targeted research, or topical application for localized inflammation studies. Reconstitute the 5 mg vial with 1-2 mL of sterile saline or bacteriostatic water. For systemic anti-inflammatory research, typical doses range from 50-200 mcg/kg administered once or twice daily. For gut health studies, oral administration of 100-300 mcg/kg is common. Research suggests optimal anti-inflammatory effects in the 100-400 mcg total dose range for standard rodent models, with effects typically measurable within hours through cytokine assays or inflammatory marker analysis.

• Acute Inflammation Protocol (1-2 weeks): 100-200 mcg/kg twice daily to investigate rapid inflammation resolution in induced injury or infection models. May be combined with BPC 157 research to examine complementary repair and anti-inflammatory mechanisms.
• Gut Health Studies (3-4 weeks): 150-300 mcg/kg orally to examine intestinal barrier protection and colitis models. Often paired with L-Glutamine research to compare peptide versus amino acid approaches to gut integrity.
• Chronic Inflammation Research (4-6 weeks): 75-150 mcg/kg daily to investigate long-term inflammation modulation in autoimmune or metabolic disorder models. Can be examined alongside NAD+ research to study inflammation-aging interactions.

Experimental Design Considerations:

For inflammation studies: Utilize cytokine profiling (IL-1β, IL-6, TNF-α, IL-10), NF-κB activation assays, and histopathological examination of affected tissues. Behavioral endpoints may include pain sensitivity measurements and activity monitoring. For gut health research: Assess intestinal permeability (FITC-dextran assay), mucosal histology, tight junction protein expression (occludin, zonulin), and fecal calprotectin levels. When researching alongside performance compounds like Winstrol 50 or Dianabol 20, monitor liver inflammation markers and gut barrier function as potential protective mechanisms.

Combination Research Protocols:

KPV combines effectively with other peptides for comprehensive inflammation and repair studies. With TB-500: KPV controls inflammation while TB-500 promotes cellular migration for complete injury resolution. With GHK-Cu 50 mg: KPV reduces inflammation while GHK-Cu promotes collagen remodeling for optimal tissue repair. With SS-31 50 mg: Combined mitochondrial protection and inflammation control for comprehensive cellular stress management. Research suggests synergistic effects when inflammation control is paired with tissue repair mechanisms.

Storage Instructions

• Unreconstituted: Store lyophilized KPV vials at 2-8°C (36-46°F) for optimal stability (up to 24 months). The tripeptide structure is relatively stable but benefits from consistent refrigeration. Avoid freezing as ice crystal formation can potentially affect the powder structure. For extended storage beyond 6 months, -20°C (-4°F) is recommended with protection from temperature fluctuations.
• Reconstituted: After mixing with appropriate vehicle (sterile saline recommended for most research), store at 2-8°C (36-46°F) and use within 14 days. KPV in solution maintains good stability compared to larger peptides. For oral administration studies, freshly prepared solutions are recommended to ensure accurate dosing and prevent microbial growth.
• Research Handling Notes: Use aseptic technique for all procedures. Protect from light exposure using amber vials or foil wrapping. For oral administration studies, consider using acid-resistant capsules or enteric coating if studying gut-specific effects. Document preparation methods, storage conditions, and administration timing as critical variables in research protocols. Aliquot into single-use volumes if planning extended studies to minimize freeze-thaw cycles.